Suppr超能文献

一种多功能非病毒载体,用于递送 MTH1 靶向的 CRISPR/Cas9 系统,用于非小细胞肺癌治疗。

A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.

机构信息

Department of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Jiangsu Suzhou 215123, China.

Department of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Jiangsu Suzhou 215123, China; Department of Pharmacy, Changzhou the Second People's Hospital Affiliated to Nanjing Medical University, Jiangsu Changzhou 213000, China.

出版信息

Acta Biomater. 2022 Nov;153:481-493. doi: 10.1016/j.actbio.2022.09.046. Epub 2022 Sep 24.

Abstract

Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system adapted from bacteria is a programmable nuclease-based genome editing tool. The long-lasting effect of gene silencing or correction is beneficial in cancer treatment. Considering the need to broaden the practical application of this technology, highly efficient non-viral vectors are urgently required. We prepared a multifunctional non-viral vector that could actively target tumor cells and deliver CRISPR/Cas9 plasmids into nuclei of cancer cells. Protamine sulfate (PS) which contains nuclear localization sequence was utilized to condense plasmid DNA and facilitate nuclei-targeted delivery. Liposome-coated protein/DNA complex avoided the degradation of nuclease in blood circulation. The obtained PS@Lip/pCas9 was further modified with distearoyl phosphoethanolamine-polyethylene glycol-hyaluronic acid (HA) to endow the vector ability to actively target tumor cell. Results suggested that PS@HA-Lip could deliver CRISPR/Cas9 plasmids into nuclei of tumor cells and induce genome editing effect. With the disruption of MTH1 (mutT homolog1) gene, the growth of non-small cell lung cancer was inhibited. Moreover, cell apoptosis in tumor tissue was promoted, and liver metastasis of non-small cell lung cancer (NSCLC) was reduced. Our study has provided a therapeutic strategy targeting MTH1 gene for NSCLC therapy. STATEMENT OF SIGNIFICANCE: CRISPR/Cas9 as a powerful tool for genome editing has drawn much attention. The long-lasting effect possesses unique advantage in cancer treatment. Non-viral vectors have high loading capacity, high safety and low immunogenicity, playing an important role in CRISPR/Cas9 delivery. In our study, a multifunctional non-viral vector for the efficient delivery of CRISPR/Cas9 plasmid was constructed. With the active targeting ligand and nuclei-targeting component, the cargo was efficiently delivered into cell nuclei and exerted genome editing effect. By using this vector, we successfully inhibited the growth and induced the apoptosis of non-small cell lung cancer by disrupting MTH1 expression with good safety. Our work provided an efficient non-vial vector for CRISPR/Cas9 delivery and explored the possibility for cancer treatment.

摘要

源自细菌的成簇规律间隔短回文重复 (CRISPR)/CRISPR 相关蛋白 9 (Cas9) 系统是一种可编程的基于核酸酶的基因组编辑工具。基因沉默或纠正的持久效果有益于癌症治疗。考虑到需要扩大这项技术的实际应用,迫切需要高效的非病毒载体。我们制备了一种多功能非病毒载体,能够主动靶向肿瘤细胞,并将 CRISPR/Cas9 质粒递送到癌细胞的核内。含有核定位序列的硫酸鱼精蛋白 (PS) 用于浓缩质粒 DNA 并促进核靶向递药。包被有脂质体的蛋白/DNA 复合物可避免核酶在血液循环中的降解。所得 PS@Lip/pCas9 进一步用二硬脂酰基磷脂酰乙醇胺-聚乙二醇-透明质酸 (HA) 进行修饰,赋予载体主动靶向肿瘤细胞的能力。结果表明,PS@HA-Lip 能够将 CRISPR/Cas9 质粒递送到肿瘤细胞核内,并诱导基因组编辑效应。通过破坏 MTH1(mutT 同源物 1)基因,抑制非小细胞肺癌的生长。此外,还促进了肿瘤组织中的细胞凋亡,并减少了非小细胞肺癌(NSCLC)的肝转移。我们的研究为 NSCLC 治疗提供了针对 MTH1 基因的治疗策略。

意义声明

CRISPR/Cas9 作为一种强大的基因组编辑工具引起了广泛关注。其持久效果在癌症治疗中具有独特的优势。非病毒载体具有高载药量、高安全性和低免疫原性的特点,在 CRISPR/Cas9 递送中发挥着重要作用。在本研究中,构建了一种用于高效递送 CRISPR/Cas9 质粒的多功能非病毒载体。通过使用主动靶向配体和核靶向组件,有效将 cargo 递送到细胞核内并发挥基因组编辑作用。通过使用该载体,我们成功地通过破坏 MTH1 表达抑制了非小细胞肺癌的生长并诱导了其凋亡,且具有良好的安全性。我们的工作为 CRISPR/Cas9 递送提供了一种高效的非病毒载体,并探索了其在癌症治疗中的可能性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验